Pfizer Inc. (NYSE:PFE) recently announced that its regulatory application for oncology candidate, axitinib has been accepted for standard review by the US Food and Drug Administration (FDA). The company is seeking approval for the treatment of patients with advanced renal cell carcinoma (RCC). The regulatory application was based on data from the phase III AXIS [...]